Literature DB >> 2965680

Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

P J Baker1, J R Hiernaux, M B Fauntleroy, B Prescott, J L Cantrell, J A Rudbach.   

Abstract

Treatment with nontoxic monophosphoryl lipid A (MPL), which was derived from a polysaccharide-deficient, heptoseless Re mutant of Salmonella typhimurium, was found to inactivate suppressor T-cell activity, as evidenced by a decrease in the degree of low-dose immunological paralysis expressed and an increase in the magnitude of the antibody response to type III pneumococcal polysaccharide. The effects produced, which could not be attributed to the polyclonal activation of immune B cells by MPL, were dependent upon the dose of MPL used, as well as the time when MPL was given relative to low-dose priming or immunization with type III pneumococcal polysaccharide. Neither amplifier nor helper T-cell activity was decreased by treatment with the same, or larger, doses of MPL. The significance of these findings to the use of MPL as an immunological adjuvant or an immunomodulating agent is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965680      PMCID: PMC259765          DOI: 10.1128/iai.56.5.1076-1083.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Regulation of the antibody response to type III pneumococcal polysaccharide. V. Ontogeny of factors influencing the magnitude of the plaque-forming cell response.

Authors:  H C Morse; B Prescott; S S Cross; P W Stashak; P J Baker
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

2.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response.

Authors:  P J Baker; P W Stashak; D F Amsbaugh; B Prescott
Journal:  Immunology       Date:  1971-04       Impact factor: 7.397

3.  Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharides at ehe cellular level.

Authors:  P H Baker; P W Stashak
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

4.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. 3. Studies on the average avidity of the antibody produced by specific plaque-forming cells.

Authors:  P J Baker; B Prescott; P W Stashak; D F Amsbaugh
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

5.  Two defects in old New Zealand Black mice are involved in the loss of low-dose paralysis to type III pneumococcal polysaccharide.

Authors:  K L McCoy; P J Baker; P W Stashak; T M Chused
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

7.  Effect of concanavalin A on lymphocyte interactions involved in the antibody response to type III pneumococcal polysaccharide. II. Ability of suppressor T cells to act on both B cells and amplified T cells to limit the magnitude of the antibody response.

Authors:  R B Markham; N D Reed; P W Stashak; B Prescott; D F Amsbaugh; P J Baker
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

8.  Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems.

Authors:  M Chun; M K Hoffmann
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

9.  Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection.

Authors:  J V Giorgi; P G Nishanian; I Schmid; L E Hultin; H L Cheng; R Detels
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

10.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

View more
  27 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Involvement of gamma interferon in antibody enhancement by adjuvants.

Authors:  M J Odean; C M Frane; M Van derVieren; M A Tomai; A G Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

3.  Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

Authors:  F Esquivel; C E Taylor; P J Baker
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

Review 4.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

5.  Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides.

Authors:  P J Baker; C E Taylor; P W Stashak; M B Fauntleroy; K Hasløv; N Qureshi; K Takayama
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

Review 6.  The role of B cells and accessory cells in the neonatal response to TI-2 antigens.

Authors:  Cheri D Landers; R Lakshman Chelvarajan; Subbarao Bondada
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide.

Authors:  P J Baker; M B Fauntleroy; P W Stashak; J R Hiernaux; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

8.  An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.

Authors:  James P Phipps; Karen M Haas
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

9.  Splenic T-lymphocyte functions during early syphilitic infection are complex.

Authors:  T J Fitzgerald; M A Tomai
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

10.  T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.

Authors:  J B Sundstrom; R Cherniak
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.